nach oben

Pediatric Nephrology

Erschienen in:

13.08.2018 | Review

Oxidative stress in chronic kidney disease

verfasst von: Kristien Daenen, Asmin Andries, Djalila Mekahli, Ann Van Schepdael, François Jouret, Bert Bammens

Erschienen in: Pediatric Nephrology | Ausgabe 6/2019

Einloggen, um Zugang zu erhalten

Abstract

Oxidative stress (OS), defined as disturbances in the pro-/antioxidant balance, is harmful to cells due to the excessive generation of highly reactive oxygen (ROS) and nitrogen (RNS) species. When the balance is not disturbed, OS has a role in physiological adaptations and signal transduction. However, an excessive amount of ROS and RNS results in the oxidation of biological molecules such as lipids, proteins, and DNA. Oxidative stress has been reported in kidney disease, due to both antioxidant depletions as well as increased ROS production. The kidney is a highly metabolic organ, rich in oxidation reactions in mitochondria, which makes it vulnerable to damage caused by OS, and several studies have shown that OS can accelerate kidney disease progression. Also, in patients at advanced stages of chronic kidney disease (CKD), increased OS is associated with complications such as hypertension, atherosclerosis, inflammation, and anemia. In this review, we aim to describe OS and its influence on CKD progression and its complications. We also discuss the potential role of various antioxidants and pharmacological agents, which may represent potential therapeutic targets to reduce OS in both pediatric and adult CKD patients.

Nur mit Berechtigung zugänglich

Locatelli F, Canaud B, Eckardt K-U, Stenvinkel P, Wanner C, Zoccali C (2003) Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant 18:1272–1280CrossRefPubMed

Birben E, Sahiner UM, Sackesen C, Erzurum S, Kalayci O (2012) Oxidative stress and antioxidant defense. World Allergy Organ J 5:9–19CrossRefPubMedPubMedCentral

Di Meo S, Reed TT, Venditti P, Victor VM (2016) Role of ROS and RNS sources in physiological and pathological conditions. Oxidative Med Cell Longev 2016:1–44

Che R, Yuan Y, Huang S, Zhang A (2014) Mitochondrial dysfunction in the pathophysiology of renal diseases. AJP Ren Physiol 306:F367–F378CrossRef

Sureshbabu A, Ryter SW, Choi ME (2015) Oxidative stress and autophagy: crucial modulators of kidney injury. Redox Biol 4:208–214CrossRefPubMedPubMedCentral

Himmelfarb J (2005) Relevance of oxidative pathways in the pathophysiology of chronic kidney disease. Cardiol Clin 23:319–330CrossRefPubMed

Popolo A, Autore G, Pinto A, Marzocco S (2013) Oxidative stress in patients with cardiovascular disease and chronic renal failure. Free Radic Res 47:346–356CrossRefPubMed

Sibal L, Agarwal SC, Home PD, Boger RH (2010) The role of asymmetric dimethylarginine (ADMA) in endothelial dysfunction and cardiovascular disease. Curr Cardiol Rev 6:82–90CrossRefPubMedPubMedCentral

Yu M, Kim YJ, Kang DH (2010) Indoxyl sulfate-induced endothelial dysfunction in patients with chronic kidney disease via an induction of oxidative stress 15. Clin J Am Soc Nephrol

10.

Ward RA, McLeish KR (1995) Polymorphonuclear leukocyte oxidative burst is enhanced in patients with chronic renal insufficiency. J Am Soc Nephrol 5:1697–1702PubMed

11.

Tbahriti HF, Kaddous A, Bouchenak M, Mekki K (2013) Effect of different stages of chronic kidney disease and renal replacement therapies on oxidant-antioxidant balance in uremic patients. Biochem Res Int 2013:358985CrossRefPubMedPubMedCentral

12.

Jankowska M, Rutkowski B, Dębska-Ślizień A (2017) Vitamins and microelement bioavailability in different stages of chronic kidney disease. Nutrients 9

13.

Stocker R, Keaney JF Jr (2004) Role of oxidative modifications in atherosclerosis. Physiol Rev 84:1381–1478CrossRefPubMed

14.

Czerska M, Mikołajewska K, Zieliński M, Gromadzińska J, Wąsowicz W (2015) Today’s oxidative stress markers. Med Pr 66:393–405CrossRefPubMed

15.

Birben E, Murat U, Md S, Sackesen C, Erzurum S, Kalayci O (2012) Oxidative stress and antioxidant defense. WAO J 5:9–19

16.

Pieczenik SR, Neustadt J (2007) Mitochondrial dysfunction and molecular pathways of disease. Exp Mol Pathol 83:84–92CrossRefPubMed

17.

Brandes RP, Kreuzer J (2005) Vascular NADPH oxidases: molecular mechanisms of activation. Cardiovasc Res 65:16–27CrossRefPubMed

18.

Lambeth JD (2007) Nox enzymes, ROS, and chronic disease: an example of antagonistic pleiotropy. Free Radic Biol Med 43:332–347CrossRefPubMedPubMedCentral

19.

Teixeira G, Szyndralewiez C, Molango S, Carnesecchi S, Heitz F, Wiesel P, Wood JM (2017) Therapeutic potential of NADPH oxidase 1/4 inhibitors. Br J Pharmacol 174:1647–1669CrossRefPubMed

20.

Chen F, Haigh S, Barman S, Fulton DJ (2012) From form to function: the role of Nox4 in the cardiovascular system. Front Physiol 3:412PubMedPubMedCentral

21.

Cai H (2005) NAD(P)H oxidase-dependent self-propagation of hydrogen peroxide and vascular disease. Circ Res 96:818–822CrossRefPubMed

22.

Förstermann U, Li H (2011) Therapeutic effect of enhancing endothelial nitric oxide synthase (eNOS) expression and preventing eNOS uncoupling. Br J Pharmacol 164:213–223CrossRefPubMedPubMedCentral

23.

Alp NJ, Channon KM (2004) Regulation of endothelial nitric oxide synthase by tetrahydrobiopterin in vascular disease. Arterioscler Thromb Vasc Biol 24:413–420CrossRefPubMed

24.

Yogalingam G, Lee AR, Mackenzie DS, Maures TJ, Rafalko A, Prill H, Berguig GY, Hague C, Christianson T, Bell SM, LeBowitz JH (2017) Cellular uptake and delivery of myeloperoxidase to lysosomes promote lipofuscin degradation and lysosomal stress in retinal cells. J Biol Chem 292:4255–4265CrossRefPubMedPubMedCentral

25.

Ray RS, Katyal A (2016) Myeloperoxidase: bridging the gap in neurodegeneration. Neurosci Biobehav Rev 68:611–620CrossRefPubMed

26.

Daugherty A, Dunn JL, Rateri DL, Heinecke JW (1994) Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest 94:437–444CrossRefPubMedPubMedCentral

27.

Brennan ML, Penn MS, Van LF, Nambi V, Shishehbor MH, Aviles RJ, Goormastic M, Pepoy ML, McErlean ES, Topol EJ, Nissen SE, Hazen SL (2003) Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 349:1595–1604CrossRefPubMed

28.

Nicholls SJ, Tang WH, Brennan D, Brennan ML, Mann S, Nissen SE, Hazen SL (2011) Risk prediction with serial myeloperoxidase monitoring in patients with acute chest pain. Clin Chem 57:1762–1770CrossRefPubMedPubMedCentral

29.

Chung HY, Baek BS, Song SH, Kim MS, Huh JI, Shim KH, Kim KW, Lee KH (1997) Xanthine dehydrogenase/xanthine oxidase and oxidative stress. Age (Omaha) 20:127–140CrossRef

30.

Pham-Huy LA, He H, Pham-Huy C (2008) Free radicals, antioxidants in disease and health. Int J Biomed Sci 4:89–96PubMedPubMedCentral

31.

Fox PL, Mazumder B, Ehrenwald E, Mukhopadhyay CK (2000) Ceruloplasmin and cardiovascular disease. Free Radic Biol Med 28:1735–1744CrossRefPubMed

32.

Ehrenwald E, Fox PL (1996) Role of endogenous ceruloplasmin in low density lipoprotein oxidation by human U937 monocytic cells. J Clin Invest 97:884–890CrossRefPubMedPubMedCentral

33.

Ehrenwald E, Chisolm GM, Fox PL (1994) Intact human ceruloplasmin oxidatively modifies low density lipoprotein. J Clin Invest 93:1493–1501CrossRefPubMedPubMedCentral

34.

Alam J, Cook JL (2007) How many transcription factors does it take to turn on the heme oxygenase-1 gene? Am J Respir Cell Mol Biol 36:166–174CrossRefPubMed

35.

Kensler TW, Wakabayashi N, Biswal S (2007) Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol 47:89–116CrossRefPubMed

36.

Lubos E, Loscalzo J, Handy DE (2011) Glutathione Peroxidase-1 in health and disease: from molecular mechanisms to therapeutic opportunities. Antioxid Redox Signal 15:1957–1997CrossRefPubMedPubMedCentral

37.

Shibahara S (2003) The heme oxygenase dilemma in cellular homeostasis: new insights for the feedback regulation of heme catabolism. Tohoku J Exp Med 200:167–186CrossRefPubMed

38.

Gonzalez-Sanchez E, Perez MJ, Nytofte NS, Briz O, Monte MJ, Lozano E, Serrano MA, Marin JJG (2016) Protective role of biliverdin against bile acid-induced oxidative stress in liver cells. Free Radic Biol Med 97:466–477CrossRefPubMed

39.

Abraham NG, Kappas A (2005) Heme oxygenase and the cardiovascular-renal system. Free Radic Biol Med 39:1–25CrossRefPubMed

40.

Nath KA (2012) Human AKI and heme oxygenase-1. J Am Soc Nephrol 23:971–974CrossRefPubMedPubMedCentral

41.

Camara NOS, Soares MP (2005) Heme oxygenase-1 (HO-1), a protective gene that prevents chronic graft dysfunction. Free Radic Biol Med 38:426–435CrossRefPubMed

42.

Amersi F, Shen X-D, Anselmo D, Melinek J, Iyer S, Southard DJ, Katori M, Volk H-D, Busuttil RW, Buelow R, Kupiec-Weglinski JW (2002) Ex vivo exposure to carbon monoxide prevents hepatic ischemia/reperfusion injury through p38 MAP kinase pathway. Hepatology 35:815–823CrossRefPubMed

43.

Battin EE, Brumaghim JL (2009) Antioxidant activity of sulfur and selenium: a review of reactive oxygen species scavenging, glutathione peroxidase, and metal-binding antioxidant mechanisms. Cell Biochem Biophys 55:1–23CrossRefPubMed

44.

Kabel AM (2014) Free radicals and antioxidants: role of enzymes and nutrition. World J Nutr Heal 2:35–38

45.

Modaresi A, Nafar M, Sahraei Z (2015) Oxidative stress in chronic kidney disease. Iran J Kidney Dis 9:165–179PubMed

46.

Padayatty SJ, Katz A, Wang Y, Eck P, Kwon O, Lee J-H, Chen S, Corpe C, Dutta A, Dutta SK, Levine M (2003) Vitamin C as an antioxidant: evaluation of its role in disease prevention. J Am Coll Nutr 22:18–35CrossRefPubMed

47.

Pandey KB, Rizvi SI (2009) Plant polyphenols as dietary antioxidants in human health and disease. Oxidative Med Cell Longev 2:270–278CrossRef

48.

Sansone R, Rodriguez-Mateos A, Heuel J, Falk D, Schuler D, Wagstaff R, Kuhnle GG, Spencer JP, Schroeter H, Merx MW, Kelm M, Heiss C (2015) Cocoa flavanol intake improves endothelial function and Framingham Risk Score in healthy men and women: a randomised, controlled, double-masked trial: the Flaviola Health Study. Br J Nutr 114:1246–1255CrossRefPubMedPubMedCentral

49.

Roche M, Rondeau P, Singh NR, Tarnus E, Bourdon E (2008) The antioxidant properties of serum albumin. FEBS Lett 582:1783–1787CrossRefPubMed

50.

Prasad AS (2008) Clinical, immunological, anti-inflammatory and antioxidant roles of zinc. Exp Gerontol 43:370–377CrossRefPubMed

51.

Shen H, Oesterling E, Stromberg A, Toborek M, MacDonald R, Hennig B (2008) Zinc deficiency induces vascular pro-inflammatory parameters associated with NF-kappaB and PPAR signaling. J Am Coll Nutr 27:577–587CrossRefPubMed

52.

Holben DH, Smith AM (1999) The diverse role of selenium within selenoproteins: a review. J Am Diet Assoc 99:836–843CrossRefPubMed

53.

Girelli D, Olivieri O, Stanzial AM, Azzini M, Lupo A, Bernich P, Menini C, Gammaro L, Corrocher R (1993) Low platelet glutathione peroxidase activity and serum selenium concentration in patients with chronic renal failure: relations to dialysis treatments, diet and cardiovascular complications. Clin Sci (Lond) 84:611–617CrossRef

54.

Kashihara N, Haruna Y, Kondeti VK, Kanwar YS (2010) Oxidative stress in diabetic nephropathy. Curr Med Chem 17:4256–4269CrossRefPubMedPubMedCentral

55.

Forbes JM, Coughlan MT, Cooper ME (2008) Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 57:1446–1454CrossRefPubMed

56.

Galvan DL, Green NH, Danesh FR (2017) The hallmarks of mitochondrial dysfunction in chronic kidney disease. Kidney Int. https://doi.org/10.1016/j.kint.2017.05.034

57.

Granata S, Zaza G, Simone S, Villani G, Latorre D, Pontrelli P, Carella M, Schena FP, Grandaliano G, Pertosa G (2009) Mitochondrial dysregulation and oxidative stress in patients with chronic kidney disease. BMC Genomics 10:388CrossRefPubMedPubMedCentral

58.

Ishimoto Y, Inagi R, Yoshihara D, Kugita M, Nagao S, Shimizu A, Takeda N, Wake M, Honda K, Zhou J, Nangaku M (2017) Mitochondrial abnormality facilitates cyst formation in autosomal dominant polycystic kidney disease. Mol Cell Biol. https://doi.org/10.1128/MCB.00337-17

59.

McClelland AD, Herman-Edelstein M, Komers R, Jha JC, Winbanks CE, Hagiwara S, Gregorevic P, Kantharidis P, Cooper ME (2015) miR-21 promotes renal fibrosis in diabetic nephropathy by targeting PTEN and SMAD7. Clin Sci (Lond) 129:1237–1249CrossRef

60.

Locatelli F, Del Vecchio L, Cavalli A (2009) Inhibition of the renin-angiotensin system in chronic kidney disease: a critical look to single and dual blockade. Nephron Clin Pract 113:c286–c293CrossRefPubMed

61.

Yacoub R, Campbell KN (2015) Inhibition of RAS in diabetic nephropathy. Int J Nephrol Renov Dis 8:29–40

62.

Dou L, Jourde-Chiche N, Faure V, Cerini C, Berland Y, gnat-George F, Brunet P (2007) The uremic solute indoxyl sulfate induces oxidative stress in endothelial cells. J Thromb Haemost 5:1302–1308CrossRefPubMed

63.

Li MS, Adesina SE, Ellis CL, Gooch JL, Hoover RS, Williams CR (2017) NADPH oxidase-2 mediates zinc deficiency-induced oxidative stress and kidney damage. Am J Phys Cell Phys 312:C47–C55CrossRef

64.

Kong X, Zhang Y, Wu H, Li F, Zhang D, Su Q (2012) Combination therapy with losartan and pioglitazone additively reduces renal oxidative and nitrative stress induced by chronic high fat, sucrose, and sodium intake. Oxidative Med Cell Longev 2012:856085CrossRef

65.

Wilson SK (1990) Role of oxygen-derived free radicals in acute angiotensin II-induced hypertensive vascular disease in the rat. Circ Res 66:722–734CrossRefPubMed

66.

Yu M, Kim YJ, Kang D-H (2011) Indoxyl sulfate-induced endothelial dysfunction in patients with chronic kidney disease via an induction of oxidative stress. Clin J Am Soc Nephrol 6:30–39CrossRefPubMedPubMedCentral

67.

Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM, Wautier JL (2001) Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 280:E685–E694CrossRefPubMed

68.

Tumur Z, Niwa T (2009) Indoxyl sulfate inhibits nitric oxide production and cell viability by inducing oxidative stress in vascular endothelial cells. Am J Nephrol 29:551–557CrossRefPubMed

69.

Perticone F, Sciacqua A, Maio R, Perticone M, Maas R, Boger RH, Tripepi G, Sesti G, Zoccali C (2005) Asymmetric dimethylarginine, L-arginine, and endothelial dysfunction in essential hypertension. J Am Coll Cardiol 46:518–523CrossRefPubMed

70.

Ueda S, Yamagishi S, Matsumoto Y, Fukami K, Okuda S (2007) Asymmetric dimethylarginine (ADMA) is a novel emerging risk factor for cardiovascular disease and the development of renal injury in chronic kidney disease. Clin Exp Nephrol 11:115–121CrossRefPubMed

71.

Correia-Costa L, Sousa T, Morato M, Cosme D, Afonso J, Moura C, Mota C, Areias JC, Guerra A, Schaefer F, Caldas Afonso A, Barros H, Albino-Teixeira A, Azevedo A (2016) Association of myeloperoxidase levels with cardiometabolic factors and renal function in prepubertal children. Eur J Clin Investig 46:50–59CrossRef

72.

Pecoits-Filho R, Stenvinkel P, Marchlewska A, Heimburger O, Barany P, Hoff CM, Holmes CJ, Suliman M, Lindholm B, Schalling M, Nordfors L (2003) A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end-stage renal disease patients. Kidney Int Suppl:S172–S176

73.

Gondouin B, Jourde-Chiche N, Sallee M, Dou L, Cerini C, Loundou A, Morange S, Berland Y, Burtey S, Brunet P, Guieu R, Dussol B (2015) Plasma xanthine oxidase activity is predictive of cardiovascular disease in patients with chronic kidney disease, independently of uric acid levels. Nephron 131:167–174CrossRefPubMed

74.

Kohagura K, Tana T, Higa A, Yamazato M, Ishida A, Nagahama K, Sakima A, Iseki K, Ohya Y (2016) Effects of xanthine oxidase inhibitors on renal function and blood pressure in hypertensive patients with hyperuricemia. Hypertens Res 39:593–597CrossRefPubMed

75.

Kuo KL, Hung SC, Lee TS, Tarng DC (2014) Iron sucrose accelerates early atherogenesis by increasing superoxide production and upregulating adhesion molecules in CKD. J Am Soc Nephrol 25:2596–2606CrossRefPubMedPubMedCentral

76.

Kennedy DJ, Fan Y, Wu Y, Pepoy M, Hazen SL, Tang WH (2014) Plasma ceruloplasmin, a regulator of nitric oxide activity, and incident cardiovascular risk in patients with CKD. Clin J Am Soc Nephrol 9:462–467CrossRefPubMed

77.

Ceballos-Picot I, Witko-Sarsat V, Merad-Boudia M, Nguyen AT, Thevenin M, Jaudon MC, Zingraff J, Verger C, Jungers P, Descamps-Latscha B (1996) Glutathione antioxidant system as a marker of oxidative stress in chronic renal failure. Free Radic Biol Med 21:845–853CrossRefPubMed

78.

Zachara BA (2015) Selenium and selenium-dependent antioxidants in chronic kidney disease. Adv Clin Chem 68:131–151CrossRefPubMed

79.

Bellisola G, Perona G, Galassini S, Moschini G, Guidi GC (1993) Plasma selenium and glutathione peroxidase activities in individuals living in the Veneto region of Italy. J Trace Elem Electrolytes Health Dis 7:242–244PubMed

80.

Courtney AE, McNamee PT, Heggarty S, Middleton D, Maxwell AP (2007) Association of functional haem oxygenase-1 gene promoter polymorphism with polycystic kidney disease and IgA nephropathy. Nephrol Dial Transplant 23:608–611CrossRefPubMed

81.

Chen YH, Hung SC, Tarng DC (2013) Length polymorphism in heme oxygenase-1 and cardiovascular events and mortality in hemodialysis patients. Clin J Am Soc Nephrol

82.

Danielski M, Ikizler TA, McMonagle E, Kane JC, Pupim L, Morrow J, Himmelfarb J (2003) Linkage of hypoalbuminemia, inflammation, and oxidative stress in patients receiving maintenance hemodialysis therapy. Am J Kidney Dis 42:286–294CrossRefPubMed

83.

Parham M, Amini M, Aminorroaya A, Heidarian E (2008) Effect of zinc supplementation on microalbuminuria in patients with type 2 diabetes: a double blind, randomized, placebo-controlled, cross-over trial. Rev Diabet Stud 5:102–109CrossRefPubMedPubMedCentral

84.

Li B, Tan Y, Sun W, Fu Y, Miao L, Cai L (2013) The role of zinc in the prevention of diabetic cardiomyopathy and nephropathy. Toxicol Mech Methods 23:27–33CrossRefPubMed

85.

Himmelfarb J, McMonagle E (2001) Albumin is the major plasma protein target of oxidant stress in uremia. Kidney Int 60:358–363CrossRefPubMed

86.

Ashor AW, Lara J, Mathers JC, Siervo M (2014) Effect of vitamin C on endothelial function in health and disease: a systematic review and meta-analysis of randomised controlled trials. Atherosclerosis 235:9–20CrossRefPubMed

87.

Boaz M, Smetana S, Weinstein T, Matas Z, Gafter U, Iaina A, Knecht A, Weissgarten Y, Brunner D, Fainaru M, Green MS (2000) Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 356:1213–1218CrossRefPubMed

88.

Rassaf T, Rammos C, Hendgen-Cotta UB, Heiss C, Kleophas W, Dellanna F, Floege J, Hetzel GR, Kelm M (2016) Vasculoprotective effects of dietary cocoa flavanols in patients on hemodialysis: a double-blind, randomized, placebo-controlled trial. Clin J Am Soc Nephrol 11:108–118CrossRefPubMed

89.

Nistala R, Whaley-Connell A, Sowers JR (2008) Redox control of renal function and hypertension. Antioxid Redox Signal 10:2047–2089CrossRefPubMedPubMedCentral

90.

Drozdz D, Kwinta P, Sztefko K, Kordon Z, Drozdz T, Łątka M, Miklaszewska M, Zachwieja K, Rudziński A, Pietrzyk JA (2016) Oxidative stress biomarkers and left ventricular hypertrophy in children with chronic kidney disease. Oxidative Med Cell Longev 2016:1–8CrossRef

91.

Garcia-Bello JA, Gómez-Díaz RA, Contreras-Rodríguez A, Talavera JO, Mondragón-González R, Sanchez-Barbosa L, Diaz-Flores M, Valladares-Salgado A, Gallardo JM, Aguilar-Kitsu A, Lagunas-Munoz J, Wacher NH (2014) Carotid intima media thickness, oxidative stress, and inflammation in children with chronic kidney disease. Pediatr Nephrol 29:273–281CrossRefPubMed

92.

Kotur-Stevuljević J, Peco-Antić A, Spasić S, Stefanović A, Paripović D, Kostić M, Vasić D, Vujović A, Jelić-Ivanović Z, Spasojević-Kalimanovska V, Kornic-Ristovski D (2013) Hyperlipidemia, oxidative stress, and intima media thickness in children with chronic kidney disease. Pediatr Nephrol 28:295–303CrossRefPubMed

93.

Chien S-J, Lin I-C, Hsu C-N, Lo M-H, Tain Y-L (2015) Homocysteine and arginine-to-asymmetric dimethylarginine ratio associated with blood pressure abnormalities in children with early chronic kidney disease. Circ J 79:2031–2037CrossRefPubMed

94.

Niwa T (2010) Indoxyl sulfate is a nephro-vascular toxin 28. J Ren Nutr 20:S2–S6CrossRefPubMed

95.

Yilmaz MI, Saglam M, Caglar K, Cakir E, Sonmez A, Ozgurtas T, Aydin A, Eyileten T, Ozcan O, Acikel C, Tasar M, Genctoy G, Erbil K, Vural A, Zoccali C (2006) The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine. Am J Kidney Dis 47:42–50CrossRefPubMed

96.

Tyagi N, Sedoris KC, Steed M, Ovechkin AV, Moshal KS, Tyagi SC (2005) Mechanisms of homocysteine-induced oxidative stress. Am J Physiol Hear Circ Physiol 289:H2649–H2656CrossRef

97.

Shao B, Pennathur S, Pagani I, Oda MN, Witztum JL, Oram JF, Heinecke JW (2010) Modifying apolipoprotein A-I by malondialdehyde, but not by an array of other reactive carbonyls, blocks cholesterol efflux by the ABCA1 pathway. J Biol Chem 285:18473–18484CrossRefPubMedPubMedCentral

98.

Boaz M, Matas Z, Biro A, Katzir Z, Green M, Fainaru M, Smetana S (1999) Serum malondialdehyde and prevalent cardiovascular disease in hemodialysis. Kidney Int 56:1078–1083CrossRefPubMed

99.

Gailly P, Jouret F, Martin D, Debaix H, Parreira KS, Nishita T, Blanchard A, Antignac C, Willnow TE, Courtoy PJ, Scheinman SJ, Christensen EI, Devuyst O (2008) A novel renal carbonic anhydrase type III plays a role in proximal tubule dysfunction. Kidney Int 74:52–61CrossRefPubMed

100.

Andries A, Daenen KEL, Jouret F, Bammens B, Mekhali D, Van Schepdael A (2018) Oxidative stress in autosomal dominant polycystic kidney disease: player and / or early predictor for disease progression? https://doi.org/10.1007/s00467-018-4004-5

101.

Yisireyili M, Shimizu H, Saito S, Enomoto A, Nishijima F, Niwa T (2013) Indoxyl sulfate promotes cardiac fibrosis with enhanced oxidative stress in hypertensive rats. Life Sci 92:1180–1185CrossRefPubMed

102.

Tumur Z, Shimizu H, Enomoto A, Miyazaki H, Niwa T (2010) Indoxyl sulfate upregulates expression of ICAM-1 and MCP-1 by oxidative stress-induced NF-kappaB activation. Am J Nephrol 31:435–441CrossRefPubMed

103.

Finch JL, Suarez EB, Husain K, Ferder L, Cardema MC, Glenn DJ, Gardner DG, Liapis H, Slatopolsky E (2011) The effect of combining an ACE inhibitor and a VDR activator on glomerulosclerosis, proteinuria and renal oxidative stress in uremic rats. Am J Physiol Ren Physiol 302:F141–149CrossRef

104.

Kajimoto H, Kai H, Aoki H, Yasuoka S, Anegawa T, Aoki Y, Ueda S, Okuda S, Imaizumi T (2012) Inhibition of eNOS phosphorylation mediates endothelial dysfunction in renal failure: new effect of asymmetric dimethylarginine. Kidney Int 81:762–768CrossRefPubMed

105.

Correia-Costa L, Sousa T, Morato M, Cosme D, Afonso J, Areias JC, Schaefer F, Guerra A, Afonso AC, Azevedo A, Albino-Teixeira A (2016) Oxidative stress and nitric oxide are increased in obese children and correlate with cardiometabolic risk and renal function. Br J Nutr 116:805–815CrossRefPubMed

106.

Marcovecchio ML, de Giorgis T, Di Giovanni I, Chiavaroli V, Chiarelli F, Mohn A (2016) Association between markers of endothelial dysfunction and early signs of renal dysfunction in pediatric obesity and type 1 diabetes. Pediatr Diabetes:1–7

107.

Lehners A, Lange S, Niemann G, Rosendahl A, Meyer-Schwesinger C, Oh J, Stahl R, Ehmke H, Benndorf R, Klinke A, Baldus S, Wenzel UO (2014) Myeloperoxidase deficiency ameliorates progression of chronic kidney disease in mice. Am J Physiol Ren Physiol 307:F407–F417CrossRef

108.

Fukai T, Ushio-Fukai M (2011) Superoxide dismutases: role in redox signaling, vascular function, and diseases. Antioxid Redox Signal 15:1583–1606CrossRefPubMedPubMedCentral

109.

Zachara BA, Koterska D, Manitius J, Sadowski L, Dziedziczko A, Salak A, Wasowicz W (2004) Selenium supplementation on plasma glutathione peroxidase activity in patients with end-stage chronic renal failure. Biol Trace Elem Res:15

110.

Bonomini M, Albertazzi A (1995) Selenium in uremia. Artif Organs 19:443–448CrossRefPubMed

111.

Fujishima Y, Ohsawa M, Itai K, Kato K, Tanno K, Turin TC, Onoda T, Endo S, Okayama A, Fujioka T (2011) Serum selenium levels are inversely associated with death risk among hemodialysis patients. Nephrol Dial Transplant 26:3331–3338CrossRefPubMed

112.

Chen Y-H, Kuo K-L, Hung S-C, Hsu C-C, Chen Y-H, Tarng D-C (2014) Length polymorphism in heme oxygenase-1 and risk of CKD among patients with coronary artery disease. J Am Soc Nephrol 25:2669–2677CrossRefPubMedPubMedCentral

113.

Daenen KEL, Martens P, Bammens B (2016) Association of HO-1 (GT)n promoter polymorphism and cardiovascular disease: a reanalysis of the literature. Can J Cardiol 32:160–168CrossRefPubMed

114.

Leaf DE, Body SC, Muehlschlegel JD, McMahon GM, Lichtner P, Collard CD, Shernan SK, Fox AA, Waikar SS (2016) Length polymorphisms in heme oxygenase-1 and AKI after cardiac surgery. J Am Soc Nephrol 27:3291–3297CrossRefPubMedPubMedCentral

115.

Kim HJ, Vaziri ND (2010) Contribution of impaired Nrf2-Keap1 pathway to oxidative stress and inflammation in chronic renal failure. Am J Physiol Ren Physiol 298:F662–F671CrossRef

116.

Abo El Gheit R, Emam MN (2016) Targeting heme oxygenase-1 in early diabetic nephropathy in streptozotocin-induced diabetic rats. Physiol Int 103:413–427CrossRefPubMed

117.

Mydlik M, Derzsiova K, Racz O, Sipulova A, Lovasova E (2006) Antioxidant therapy by oral vitamin E and vitamin E-coated dialyzer in CAPD and haemodialysis patients 48. Prague Med Rep 107:354–364PubMed

118.

Lobo JC, Torres JP, Fouque D, Mafra D (2010) Zinc deficiency in chronic kidney disease: is there a relationship with adipose tissue and atherosclerosis? Biol Trace Elem Res 135:16–21CrossRefPubMed

119.

Mafra D, Cuppari L, Cozzolino SM (2002) Iron and zinc status of patients with chronic renal failure who are not on dialysis. J Ren Nutr 12:38–41CrossRefPubMed

120.

Esfahani ST, Hamidian MR, Madani A, Ataei N, Mohseni P, Roudbari M, Haddadi M (2006) Serum zinc and copper levels in children with chronic renal failure. Pediatr Nephrol 21:1153–1156CrossRefPubMed

121.

Zwolinska D, Morawska Z, Dobracka A, Miler M, Makulska I, Krol Z (1993) Concentration of selected trace elements in serum and erythrocytes of children with chronic renal failure and am attempt at deficiency correction with animal blood preparation. Wiad Lek 46:116–119PubMed

122.

Karamouzis I, Sarafidis PA, Karamouzis M, Iliadis S, Haidich AB, Sioulis A, Triantos A, Vavatsi-Christaki N, Grekas DM (2008) Increase in oxidative stress but not in antioxidant capacity with advancing stages of chronic kidney disease. Am J Nephrol 28:397–404CrossRefPubMed

123.

Nguyen-Khoa T, Massy ZA, Witko-Sarsat V, Thevenin M, Touam M, Lambrey G, Lacour B, Drueke TB, Descamps-Latscha B (1999) Critical evaluation of plasma and LDL oxidant-trapping potential in hemodialysis patients. Kidney Int 56:747–753CrossRefPubMed

124.

Sato E, Tanaka A, Oyama J-I, Yamasaki A, Shimomura M, Hiwatashi A, Ueda Y, Amaha M, Nomura M, Matsumura D, Nakamura T, Node K (2016) Long-term effects of AST-120 on the progression and prognosis of pre-dialysis chronic kidney disease: a 5-year retrospective study. Heart Vessel 31:1625–1632CrossRef

125.

Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Suzuki T, Ueda Y, Yamagishi S (2011) Oral adsorbent AST-120 ameliorates tubular injury in chronic renal failure patients by reducing proteinuria and oxidative stress generation 1. Metabolism 60:260–264CrossRefPubMed

126.

Hisaki R, Fujita H, Saito F, Kushiro T (2005) Tempol attenuates the development of hypertensive renal injury in Dahl salt-sensitive rats. Am J Hypertens 18:707–713CrossRefPubMed

127.

Nishiyama A, Yoshizumi M, Hitomi H, Kagami S, Kondo S, Miyatake A, Fukunaga M, Tamaki T, Kiyomoto H, Kohno M, Shokoji T, Kimura S, Abe Y (2004) The SOD mimetic tempol ameliorates glomerular injury and reduces mitogen-activated protein kinase activity in Dahl salt-sensitive rats. J Am Soc Nephrol 15:306–315CrossRefPubMed

128.

Tang Y, Yang Q, Lu J, Zhang X, Suen D, Tan Y, Jin L, Xiao J, Xie R, Rane M, Li X, Cai L (2010) Zinc supplementation partially prevents renal pathological changes in diabetic rats. J Nutr Biochem 21:237–246CrossRefPubMed

129.

Soinio M, Marniemi J, Laakso M, Pyorala K, Lehto S, Ronnemaa T (2007) Serum zinc level and coronary heart disease events in patients with type 2 diabetes. Diabetes Care 30:523–528CrossRefPubMed

130.

de Zeeuw D, Akizawa T, Agarwal R, Audhya P, Bakris GL, Chin M, Krauth M, Lambers Heerspink HJ, Meyer CJ, McMurray JJ, Parving HH, Pergola PE, Remuzzi G, Toto RD, Vaziri ND, Wanner C, Warnock DG, Wittes J, Chertow GM (2013) Rationale and trial design of bardoxolone methyl evaluation in patients with chronic kidney disease and type 2 diabetes: the occurrence of renal events (BEACON). Am J Nephrol 37:212–222CrossRefPubMed

131.

Pergola PE, Raskin P, Toto RD, Meyer CJ, Huff JW, Grossman EB, Krauth M, Ruiz S, Audhya P, Christ-Schmidt H, Wittes J, Warnock DG (2011) Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 365:327–336CrossRefPubMed

132.

de Zeeuw D, Akizawa T, Audhya P, Bakris GL, Chin M, Christ-Schmidt H, Goldsberry A, Houser M, Krauth M, Lambers Heerspink HJ, McMurray JJ, Meyer CJ, Parving HH, Remuzzi G, Toto RD, Vaziri ND, Wanner C, Wittes J, Wrolstad D, Chertow GM (2013) Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med 369:2492–2503CrossRefPubMedPubMedCentral

133.

Chin MP, Reisman SA, Bakris GL, O’Grady M, Linde PG, McCullough PA, Packham D, Vaziri ND, Ward KW, Warnock DG, Meyer CJ (2014) Mechanisms contributing to adverse cardiovascular events in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl. Am J Nephrol 39:499–508CrossRefPubMed

134.

Van Laecke S, Van Biesen W, Vanholder R (2015) The paradox of bardoxolone methyl: a call for every witness on the stand? Diabetes Obes Metab 17:9–14CrossRefPubMed

135.

Jun M, Venkataraman V, Razavian M, Cooper B, Zoungas S, Ninomiya T, Webster AC, Perkovic V (2012) Antioxidants for chronic kidney disease. Cochrane Database Syst Rev 10:CD008176. https://doi.org/10.1002/14651858.CD008176.pub2 CrossRefPubMed

136.

Ding W, Wang B, Zhang M, Gu Y (2015) Tempol, a superoxide dismutase-mimetic drug, ameliorates progression of renal disease in CKD mice. Cell Physiol Biochem 36:2170–2182CrossRefPubMed

137.

Vanholder R, Massy Z, Argiles A, Spasovski G, Verbeke F, Lameire N (2005) Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 20:1048–1056CrossRefPubMed

138.

Foley RN (2010) Clinical epidemiology of cardiovascular disease in chronic kidney disease. J Ren Care 36(Suppl 1):4–8CrossRefPubMed

139.

Groothoff JW, Offringa M, Grootenhuis M, Jager KJ (2017) Long-term consequences of renal insufficiency in children: lessons learned from the Dutch LERIC study. Nephrol Dial Transplant 33:552–560CrossRef

140.

Mcdonald SP, Craig JC (2004) Long-term survival of children with end-stage renal disease. N Engl J Med 350:2654–2662CrossRefPubMed

141.

Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM (2002) The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 62:1524–1538CrossRefPubMed

142.

Fliser D (2005) Asymmetric dimethylarginine (ADMA): the silent transition from an “uraemic toxin” to a global cardiovascular risk molecule. Eur J Clin Investig 35:71–79CrossRef

143.

Togliatto G, Lombardo G, Brizzi MF (2017) The future challenge of reactive oxygen species (ROS) in hypertension: from bench to bed side. Int J Mol Sci 18

144.

Ali F, Hamdulay SS, Kinderlerer AR, Boyle JJ, Lidington EA, Yamaguchi T, Soares MP, Haskard DO, Randi AM, Mason JC (2007) Statin-mediated cytoprotection of human vascular endothelial cells: a role for Kruppel-like factor 2-dependent induction of heme oxygenase-1. J Thromb Haemost 5:2537–2546CrossRefPubMed

145.

Bertrand ME (2004) Provision of cardiovascular protection by ACE inhibitors: a review of recent trials. Curr Med Res Opin 20:1559–1569CrossRefPubMed

146.

El-Mesallamy HO, Abdel Hamid SG, Gad MZ (2008) Oxidative stress and asymmetric dimethylarginine are associated with cardiovascular complications in hemodialysis patients: improvements by L-arginine intake. Kidney Blood Press Res 31:189–195CrossRefPubMed

147.

Fliser D, Kielstein JT, Haller H, Bode-Boger SM (2003) Asymmetric dimethylarginine: a cardiovascular risk factor in renal disease? Kidney Int Suppl:S37–S40

148.

Maas R, Xanthakis V, Polak JF, Schwedhelm E, Sullivan LM, Benndorf R, Schulze F, Vasan RS, Wolf PA, Boger RH, Seshadri S (2009) Association of the endogenous nitric oxide synthase inhibitor ADMA with carotid artery intimal media thickness in the Framingham Heart Study offspring cohort. Stroke 40:2715–2719CrossRefPubMedPubMedCentral

149.

Speer T, Rohrer L, Blyszczuk P, Shroff R, Kuschnerus K, Kränkel N, Kania G, Zewinger S, Akhmedov A, Shi Y, Martin T, Perisa D, Winnik S, Müller MF, Sester U, Wernicke G, Jung A, Gutteck U, Eriksson U, Geisel J, Deanfield J, von Eckardstein A, Lüscher TF, Fliser D, Bahlmann FH, Landmesser U (2013) Abnormal high-density lipoprotein induces endothelial dysfunction via activation of toll-like receptor-2. Immunity 38:754–768CrossRefPubMed

150.

Shroff R, Speer T, Colin S, Charakida M, Zewinger S, Staels B, Chinetti-Gbaguidi G, Hettrich I, Rohrer L, O’Neill F, McLoughlin E, Long D, Shanahan CM, Landmesser U, Fliser D, Deanfield JE (2014) HDL in children with CKD promotes endothelial dysfunction and an abnormal vascular phenotype. J Am Soc Nephrol 25:2658–2668CrossRefPubMedPubMedCentral

151.

Kaseda R, Jabs K, Hunley TE, Jones D, Bian A, Allen RM, Vickers KC, Yancey PG, Linton MF, Fazio S, Kon V (2015) Dysfunctional high-density lipoproteins in children with chronic kidney disease. Metabolism 64:263–273CrossRefPubMed

152.

Hadtstein C, Schaefer F (2008) Hypertension in children with chronic kidney disease: pathophysiology and management. Pediatr Nephrol 23:363–371CrossRefPubMed

153.

Hussein G, Bughdady Y, Kandil ME, Bazaraa HM, Taher H (2008) Doppler assessment of brachial artery flow as a measure of endothelial dysfunction in pediatric chronic renal failure. Pediatr Nephrol 23:2025–2030CrossRefPubMed

154.

Wilson AC, Urbina E, Witt SA, Glascock BJ, Kimball TR, Mitsnefes M (2008) Flow-mediated vasodilatation of the brachial artery in children with chronic kidney disease. Pediatr Nephrol 23:1297–1302CrossRefPubMed

155.

Khandelwal P, Murugan V, Hari S, Lakshmy R, Sinha A, Hari P, Bagga A (2016) Dyslipidemia, carotid intima-media thickness and endothelial dysfunction in children with chronic kidney disease. Pediatr Nephrol 31:1313–1320CrossRefPubMed

156.

Mitsnefes MM, Kimball TR, Kartal J, Witt SA, Glascock BJ, Khoury PR, Daniels SR (2006) Progression of left ventricular hypertrophy in children with early chronic kidney disease: 2-year follow-up study. J Pediatr 149:671–675CrossRefPubMed

157.

Mitsnefes M, Flynn J, Cohn S, Samuels J, Blydt-Hansen T, Saland J, Kimball T, Furth S, Warady B (2010) Masked hypertension associates with left ventricular hypertrophy in children with CKD. J Am Soc Nephrol 21:137–144CrossRefPubMedPubMedCentral

158.

Kupferman JC, Aronson Friedman L, Cox C, Flynn J, Furth S, Warady B, Mitsnefes M (2014) BP control and left ventricular hypertrophy regression in children with CKD. J Am Soc Nephrol 25:167–174CrossRefPubMed

159.

Moody WE, Edwards NC, Chue CD, Ferro CJ, Townend JN (2013) Arterial disease in chronic kidney disease. Heart 99:365–372CrossRefPubMed

160.

London G, Covic A, Goldsmith D, Wiecek A, Suleymanlar G, Ortiz A, Massy Z, Lindholm B, Martinez-Castelao A, Fliser D, Agarwal R, Jager KJ, Dekker FW, Blankestijn PJ, Zoccali C (2011) Arterial aging and arterial disease: interplay between central hemodynamics, cardiac work, and organ flow-implications for CKD and cardiovascular disease. Kidney Int Suppl 1:10–12CrossRef

161.

Vervloet M, Cozzolino M (2017) Vascular calcification in chronic kidney disease: different bricks in the wall? Kidney Int 91:808–817CrossRefPubMed

162.

Chirinos JA (2012) Arterial stiffness: basic concepts and measurement techniques. J Cardiovasc Transl Res 5:243–255CrossRefPubMed

163.

Wilson AC, Mitsnefes MM (2009) Cardiovascular disease in CKD in children: update on risk factors, risk assessment, and management. Am J Kidney Dis 54:345–360CrossRefPubMedPubMedCentral

164.

Ma Y, Zhou L, Dong J, Zhang X, Yan S (2015) Arterial stiffness and increased cardiovascular risk in chronic kidney disease. Int Urol Nephrol 47:1157–1164CrossRefPubMed

165.

Choi HY, Park SK, Yun GY, Choi AR, Lee JE, Ha SK, Park HC (2016) Glycated albumin is independently associated with arterial stiffness in non-diabetic chronic kidney disease patients. Medicine 95:e3362CrossRefPubMedPubMedCentral

166.

Nishizawa Y, Koyama H, Inaba M (2012) AGEs and cardiovascular diseases in patients with end-stage renal diseases. J Ren Nutr 22:128–133CrossRefPubMed

167.

Rossi M, Campbell KL, Johnson DW, Stanton T, Vesey DA, Coombes JS, Weston KS, Hawley CM, McWhinney BC, Ungerer JPJ, Isbel N (2014) Protein-bound uremic toxins, inflammation and oxidative stress: a cross-sectional study in stage 3-4 chronic kidney disease. Arch Med Res 45:309–317CrossRefPubMed

168.

Gao H, Liu S (2017) Role of uremic toxin indoxyl sulfate in the progression of cardiovascular disease. Life Sci 185:23–29CrossRefPubMed

169.

Annavarajula SK, Dakshinamurty KV, Naidu MU, Reddy CP (2012) The effect of L-arginine on arterial stiffness and oxidative stress in chronic kidney disease. Indian J Nephrol 22:340–346CrossRefPubMedPubMedCentral

170.

Schuchardt M, Herrmann J, Tolle M, van der Giet M (2017) Xanthine oxidase and its role as target in cardiovascular disease: cardiovascular protection by enzyme inhibition? Curr Pharm Des 23:3391–3404CrossRefPubMed

171.

MacIsaac RL, Salatzki J, Higgins P, Walters MR, Padmanabhan S, Dominiczak AF, Touyz RM, Dawson J (2016) Allopurinol and cardiovascular outcomes in adults with hypertension. Hypertension 67:535–540CrossRefPubMed

172.

Valko M, Morris H, Cronin MTD (2005) Metals, toxicity and oxidative stress. Curr Top Med Chem 12:1161–1208CrossRef

173.

Atkinson MA, Warady BA (2017) Anemia in chronic kidney disease. Pediatr Nephrol:1–12

174.

Locatelli F, Barany P, Covic A, De FA, Del VL, Goldsmith D, Horl W, London G, Vanholder R, Van BW (2013) Kidney disease: improving global outcomes guidelines on anaemia management in chronic kidney disease: a European renal best practice position statement. Nephrol Dial Transplant 28:1346–1359CrossRefPubMed

175.

Baracco R, Saadeh S, Valentini R, Kapur G, Jain A, Mattoo TK (2011) Iron deficiency in children with early chronic kidney disease. Pediatr Nephrol 26:2077–2080CrossRefPubMed

176.

Koshy SM, Geary DF (2008) Anemia in children with chronic kidney disease. Pediatr Nephrol 23:209–219CrossRefPubMed

177.

Dursun I, Poyrazoglu HM, Gunduz Z, Ulger H, Yýkýlmaz A, Dusunsel R, Patýroglu T, Gurgoze M (2009) The relationship between circulating endothelial microparticles and arterial stiffness and atherosclerosis in children with chronic kidney disease. Nephrol Dial Transplant 24:2511–2518CrossRefPubMed

178.

Castilla P, Echarri R, Davalos A, Cerrato F, Ortega H, Teruel JL, Lucas MF, Gomez-Coronado D, Ortuno J, Lasuncion MA (2006) Concentrated red grape juice exerts antioxidant, hypolipidemic, and antiinflammatory effects in both hemodialysis patients and healthy subjects. Am J Clin Nutr 84:252–262CrossRefPubMed

Titel: Oxidative stress in chronic kidney disease
verfasst von: Kristien Daenen
Asmin Andries
Djalila Mekahli
Ann Van Schepdael
François Jouret
Bert Bammens
Publikationsdatum: 13.08.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Pediatric Nephrology / Ausgabe 6/2019
Print ISSN: 0931-041X
Elektronische ISSN: 1432-198X
DOI: https://doi.org/10.1007/s00467-018-4005-4

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Oxidative stress in chronic kidney disease

Abstract

Neu im Fachgebiet Pädiatrie

Ähnliche Überlebensraten nach Reanimation während des Transports bzw. vor Ort

Alter der Mutter beeinflusst Risiko für kongenitale Anomalie

Begünstigt Bettruhe der Mutter doch das fetale Wachstum?

Bei Amblyopie früher abkleben als bisher empfohlen?

Update Pädiatrie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2019

Patent ductus arteriosus is associated with acute kidney injury in the preterm infant

HNF1B nephropathy has a slow-progressive phenotype in childhood—with the exception of very early onset cases: results of the German Multicenter HNF1B Childhood Registry

Blood-borne viral infections in pediatric hemodialysis

Spinal cord lesions in a pediatric patient with chronic kidney disease and review of literature: Questions

Renal mass in a 2-year-old girl: Answers

Augmented renal clearance: a common condition in critically ill children

Neu im Fachgebiet Pädiatrie

Ähnliche Überlebensraten nach Reanimation während des Transports bzw. vor Ort

Alter der Mutter beeinflusst Risiko für kongenitale Anomalie

Begünstigt Bettruhe der Mutter doch das fetale Wachstum?

Bei Amblyopie früher abkleben als bisher empfohlen?

Update Pädiatrie